Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor

Interactions between the central nervous system and pancreatic islet secretions: a historical perspective

(2013) Denovan P. Begg et al.   ADVANCES IN PHYSIOLOGY EDUCATION

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

(2013) Astrid Plamboeck et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease

(2013) Karen L. Teff et al.   DIABETES

Atypical antipsychotics and diabetic ketoacidosis: a review

(2013) Melanie D. Guenette et al.   PSYCHOPHARMACOLOGY

Insulin reduces excitation in gastric-related neurons of the dorsal motor nucleus of the vagus

(2012) Camille B. Blake et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Novel Approaches to Studying the Role of Innervation in the Biology of Pancreatic Islets

(2012) Rayner Rodriguez-Diaz et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Brain Control of Insulin and Glucagon Secretion

(2012) Mayowa A. Osundiji et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Critical metabolic roles of β-cell M3 muscarinic acetylcholine receptors

(2012) Inigo Ruiz de Azua et al.   LIFE SCIENCES

Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone

(2012) Peter Manu et al.   SCHIZOPHRENIA RESEARCH

Central control of glucose homeostasis: the brain – endocrine pancreas axis

(2011) B. Thorens   DIABETES & METABOLISM

The gut-brain axis: a major glucoregulatory player

(2011) R. Burcelin   DIABETES & METABOLISM

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

(2011) Alessandro Zuddas et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

(2011) Katrina Weston-Green et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

(2011) M. De Hert et al.   EUROPEAN PSYCHIATRY

Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats

(2011) Kansuke Fujiwara et al.   JOURNAL OF NEUROCHEMISTRY

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

(2011) Marc De Hert et al.   Nature Reviews Endocrinology

Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain : Impact of antipsychotic drug treatment

(2011) Lucinda J. Steward et al.   NEUROPHARMACOLOGY

Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats

(2011) H.N. Boyda et al.   NEUROPHARMACOLOGY

A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers

(2011) Vance L. Albaugh et al.   PLoS One

Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model

(2011) Margaret Hahn et al.   SCHIZOPHRENIA RESEARCH

Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: Validation with olanzapine and ziprasidone

(2010) Miwako Shobo et al.   BEHAVIOURAL BRAIN RESEARCH

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats

(2010) Katrina Weston-Green et al.   BEHAVIOURAL BRAIN RESEARCH

Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance

(2010) P. J. F. Martins et al.   DIABETES

Beneficial Metabolic Effects Caused by Persistent Activation of β-Cell M3Muscarinic Acetylcholine Receptors in Transgenic Mice

(2010) Dinesh Gautam et al.   ENDOCRINOLOGY

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

(2010) C.U. Correll   EUROPEAN PSYCHIATRY

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study

(2010) Ahmed Elsayem et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis

(2010) V L Albaugh et al.   MOLECULAR PSYCHIATRY

Estrogen Replacement Reverses Olanzapine-Induced Weight Gain and Hepatic Insulin Resistance in Ovariectomized Diabetic Rats

(2010) Sunmin Park et al.   NEUROPSYCHOBIOLOGY

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design

(2010) Roberto Coccurello et al.   PHARMACOLOGY & THERAPEUTICS

Olanzapine affects locomotor activity and meal size in male rats

(2010) Esther M. van der Zwaal et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1

(2010) K. C. Kong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model

(2010) Heidi N. Boyda et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

(2010) Chih-Chiang Chiu et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implications

(2010) Inigo Ruiz de Azua et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Preclinical models of antipsychotic drug-induced metabolic side effects

(2010) Heidi N. Boyda et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

(2009) S. M. Stahl et al.   ACTA PSYCHIATRICA SCANDINAVICA

Hepatic Muscarinic Acetylcholine Receptors Are Not Critically Involved in Maintaining Glucose Homeostasis in Mice

(2009) Jian H. Li et al.   DIABETES

Muscarinic M1, M3 receptors function in the brainstem of streptozotocin induced diabetic rats: Their role in insulin secretion from the pancreatic islets as a function of age

(2009) Savitha Balakrishnan et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

(2009) F.C.J. Starrenburg et al.   EUROPEAN PSYCHIATRY

Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment

(2009) Rocio Perez-Iglesias et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice

(2009) Roberto Coccurello et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

(2009) Bo Ahrén   NATURE REVIEWS DRUG DISCOVERY

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

The versatility of the vagus

(2009) Graham J. Dockray   PHYSIOLOGY & BEHAVIOR

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth

(2009) D. Gautam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model

(2009) Araba F. Chintoh et al.   SCHIZOPHRENIA RESEARCH

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study

(2008) Ren-Rong Wu et al.   AMERICAN JOURNAL OF PSYCHIATRY

Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing

(2008) C. Knauf et al.   DIABETES

Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study

(2008) P. Oriot et al.   DIABETES & METABOLISM

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat

(2008) G. C. Smith et al.   DIABETOLOGIA

Role of the cholinergic system in the pathology and treatment of schizophrenia

(2008) Elizabeth Scarr et al.   Expert Review of Neurotherapeutics

Insulin Resistance and Decreased Glucose-Stimulated Insulin Secretion After Acute Olanzapine Administration

(2008) Araba F. Chintoh et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Tumor necrosis factor-α, interleukin-1β and nitric oxide induce calcium transients in distinct populations of cells cultured from the rat area postrema

(2008) Florian Wuchert et al.   JOURNAL OF NEUROIMMUNOLOGY

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

(2008) E Scarr et al.   MOLECULAR PSYCHIATRY

Disruption in the leptin–NPY link underlies the pandemic of diabetes and metabolic syndrome: New therapeutic approaches

(2008) Satya P. Kalra   NUTRITION

Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use

(2008) David Pickar et al.   PLoS One

The vagus nerve, food intake and obesity

(2008) Hans-Rudolf Berthoud   REGULATORY PEPTIDES